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Abstract 
Infection with SARS-CoV-2 can lead to COVID-19. The gastrointestinal tract is now an 
appreciated portal of infection. SARS-CoV-2 enters host cells via angiotensin converting 
enzyme-2 (ACE2) and the serine protease TMPRSS2. Eosinophilic gastrointestinal disorders 
are inflammatory conditions caused by chronic type 2 (T2) inflammation. However, the 
effects of the T2 atopic inflammatory milieu  on SARS-COV-2 viral entry gene expression in 
the GI tract is poorly understood. 
We analyzed tissue ACE2 and TMPRSS2 gene expression in pediatric eosinophilic 
esophagitis (EoE), eosinophilic gastritis (EG) and in normal adult esophagi using publicly 
available RNA sequencing datasets. Similar to findings evaluating the airway, there was no 
difference in tissue ACE2/TMPRSS2 expression in EoE or EG when compared to control 
non-EoE/EG esophagus/stomach. ACE2 gene expression was significantly lower in esophagi 
from children with or without EoE  and from adults with EoE as compared to normal  adult 
esophagi. Type 2 immunity and pediatric age could be protective for infection by SARS-
CoV-2 in the gastrointestinal tract due to decreased expression of ACE2. 
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What is known 
 Coronavirus induced disease-2019 (COVID-19) has rapidly spread around the world,
infecting millions of people and causing both respiratory and gastrointestinal
symptoms.
 ACE2 and TMPRSS2 are the major portals of entry that allow SAR-CoV2 entry at
epithelial barriers.
 The gastrointestinal tract is a potential nidus of SARS-CoV-2 infection with high
levels of ACE2 expression in the esophagus reported.
What is new 
 Normal adult esophagi have higher expression of ACE2 compared to adults with EoE.
 Children with and without EoE have lower levels of esopahgeal ACE2 gene
expression compared with normal adult esophagi.
 Adults and children with EoE express less TMPRSS2 compared to non-EoE adults.
Abbreviations:  
ACE1, 2: angiotensin converting enzyme-1, -2 
AGT: angiotensinogen 
AGTR1, 2: angiotensin receptor-1, -2  
ANG: angiotensinogen  
COVID-19: coronavirus induced disease-2019 
DEG: differentially expressed gene  
ds: double stranded  
EG: eosinophilic gastritis  
EGID: eosinophilic gastrointestinal disorder 
EoE: eosinophilic esophagitis   
GI: gastrointestinal  
R-A system: renin angiotensin system
REN: renin
RNAseq: RNA sequencing
SARS-CoV-2: severe acute respiratory syndrome coronavirus-2
ss: single stranded
TMPRSS2: transmembrane serine protease 2
TPM: transcripts per million
FPKM: fragments per kilobase of exon model per million reads mapped
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Introduction 
Since December 2019, a fast-moving global pandemic, coronavirus induced disease-
2019 (COVID-19), has ensued with over 1 million deaths worldwide.
1
 Severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) enters host cells via ACE2, a member of 
the renin angiotensin system (R-A system), and the serine protease, TMPRSS2.
2
 New
evidence demonstrates that SARS-CoV-2 can infect and be harbored in the gastrointestinal 
(GI) tract.
3
While T2 inflammatory atopic diseases are common, they do not necessarily associate 
with worsening COVID-19 risk. 
4,5
 Jackson et al demonstrated that ACE2 expression in nasal
airway epithelium was significantly decreased in atopic asthmatics compared to non-atopic 
asthmatics. Children also are relatively protected, with substantially lower morbidity and 
mortality rates from COVID-19. 
6,7
 Eosinophilic gastrointestinal disorders, especially EoE
and EG, are increasing in prevalence and caused by T2 bowel inflammation. The current 
clinical data demonstrate that patients with EGIDs do not have worse COVID-19 and, despite 
the ability of SARSCoV-2 to infect the esophagus
3
, there are no reports of COVID-19
infection in EoE.  It is not currently clear if T2 inflammation associated with EGIDs could 
decrease the ability of SARSCoV-2 to infect the esophagus, stomach or bowel. However, 
given the increasing prevalence of EGIDs, this is a salient question.
8
While ACE2 classically works in the renin-angiotensin (R-A) system to regulate 
blood pressure, it is also an important mediator of inflammation (Figure 1A).
9
 The
differential expression of ACE2 and the R-A system by age, organ system, and in the 
presence of inflammation has become of heightened interest due to the COVID-19 pandemic.  
ACE1 conversion of angiotensinogen to angiotensin 2 and its subsequent binding to 
angiotensin receptors-1 and -2 (AGTR1, 2) leads to inflammation.  ACE2 mediated 
conversion of angiotensin 2 to angiotensin 1-7 results in anti-inflammatory effects. For this 
reason, we aimed to understand the expression of not only ACE2 but also R-A system genes 
in the tissue of EoE and EG patients as compared to non-inflamed control subjects.  We 
further evaluated TMPRSS2 expression in these patient populations since spike protein 
cleavage by TMPRSS2 is required for ACE2 mediated cell entry of SARSCoV-2
2
.
Herein, we study the influence of age and EoE or EG disease state on ACE-2, 
TMPRSS-2, and R-A system gene expression using RNA sequencing data from patients who 
were, in part, from the multicenter Consortium for Eosinophilic Gastrointestinal Research 
(CEGIR). We hypothesize that the pediatric esophagus may be less vulnerable than the adult 
esophagus to infection by SARSCoV-2 and that T2 inflammation associated with EGIDs can 
influence esophageal ACE-2 and TMPRSS2 expression. 
Methods 
Datasets 
Publicly available RNA-Seq data were used for esophageal biopsy specimens of 
children with EoE (n=7) or control subjects (n=6) (GSE58640), gastric biopsy specimens 
from patients with eosinophilic gastritis (EG) (n=9) or control (n=12) subjects (EGID 
express: https://egidexpress.research. cchmc.org/data/). Patients who were designated as 
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controls had no pathologic findings on their endoscopies.  The available RNA-Seq data were 
stored in different formats such as read count, TPM, and FPKM. This hinders the integrative 
analysis of the RNA-Seq data. To ensure fair comparisons across different datasets, we 
converted RNA-Seq count data (GSE58640) to transcripts per million (TPM). Eight total 
genes were analyzed in the RNAseq dataset. The esophagus of normal adults transcriptomic 
data were downloaded from GTEx Portal (https://gtexportal.org/home/datasets). Specifically, 
the gene read counts of the RNA-Seq GTEx version 8 data set (GTEx_Analysis_2017-06-
05_v8_RNASeQCv1.1.9_gene_tpm.gct.gz) were downloaded. The sample annotations were 
also downloaded from the GTEx Portal (https://gtexportal.org/home/histologyPage) by 
selecting the Tissue = “Esophagus - Mucosa”. Data was further selected to include normal 
esophageal mucosa with no histologic abnormalities from people ages 20-59 (n=184).  
Atopy was defined as in the original publications.
10,11
  In the EG and EoE cohorts, 
atopy was defined as the presence of asthma, allergic rhinitis, atopic dermatitis, and/or food 
allergy. 
Quantification  
 For the raw data of esophageal biopsy specimens of patients with EoE or control 
subjects (GSE58640), RNA-Seq quality was assessed using FastQC.
 
Adapter sequences and 
low-quality bases were trimmed using Trimmomatic. Sequence alignment was performed 
using STAR against the Human genome (GRCH.38; GCF_000001405.38) with the default 
parameters. The expression of each gene was quantified using HTSeq
 
and converted the count 
data to transcripts per million (TPM) for further analysis. 
Statistics 
Differential gene expression was performed between different pairwise disease states 
comparisons for the 8 genes (ACE, ACE2, AGT, AGTR1, AGTR2, MAS1, REN, and 
TMPRSS2) of the renin angiotensin pathway using the limma package in R
12
. in which the p 
values were derived for all genes. The p values were further adjusted to multiple testing for 
each gene using false discovery rate (FDR) method by the Benjamini-Hochberg
13
.  Genes 
with an FDR adjusted p value < 0.05 were defined as differential expressed genes. For the 
comparisons of ACE2 and TMPRSS2 genes across different conditions, we applied the 
Wilcoxon rank-sum test on their gene expressions (TPM) in the studied conditions. Genes 
were considered as statistically significant differential expression at p < 0.05.  
Results 
 RNA sequencing data from children with EoE (mean age=6 years, range 3-10 years 
old) or non-inflamed control esophagus (mean age=13 years, range 2-17 years old) and EG 
patients (mean age=16 years, range 7-31 years old) or non-inflamed control stomach (mean 
age=15 years, range 8-28 years old) was compared for R-A system and TMPRSS2 gene 
expression. Comparative transcriptomics of active EoE and EG tissue demonstrated that EoE 
and EG patients had similar ACE2 and TMPRSS2 expression when compared with non-
inflamed esophagi or stomach from control subjects (Figure 1B,C). Of the R-A system genes, 
REN expression was significantly lower in patients with active EoE (Figure 1B).  Within the 
R-A system, AGTR1 and REN were differentially expressed and downregulated in active EG 
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as compared to non-inflamed stomach from control subjects (Figure 1C). On single gene 
pairwise comparison, EoE patients with concurrent atopy (n=8)  had significantly lower 
esophageal expression of TMPRSS2 as compared with non-atopic EoE patients (n=2) (p<.05) 
however this was not significant using multiple gene comparisons, likely due to the small 
sample size (Figure 1D).   
COVID-19 is a milder disease in children, perhaps due to differences in the 
expression level of SARS-CoV-2 entry proteins.
7
 Therefore, we evaluated expression levels
of viral receptors in the context of age.  Since control patients with non-inflamed esophagi 
have symptoms that warrant endoscopy and since our dataset contained only pediatric control 
subjects, we utilized RNA sequence data from normal adult esophagi. Normal pediatric 
samples are not available in this database. We compared the esophageal expression of ACE2 
and TMPRSS2 in normal adults as compared to non-EoE children.  ACE2 was expressed at 
significantly higher levels in the adult normal, as compared with the pediatric control, 
esophagus (Figure 2A).  
To assess the expression of ACE2 and TMPRSS2 in the context T2 eosinophilic 
inflammation as compared to a histologically normal esophagus, we compared ACE2 and 
TMPRSS2 gene expression in the esophagus of normal and EoE adults. We also compared 
the expression level of ACE2 and TMPRSS2 in children with EoE to that in the normal adult 
esophagus. ACE2 was expressed at significantly higher levels in the esophagus of normal 
adults as compared with adult or pediatric EoE patients (Figure 2B and C). Interestingly, 
esophageal specimens from both adult and pediatric EoE subjects also expressed significantly 
less TMPRSS2 as compared to normal adults (Figure 2B and C). Together, these data support 
the hypothesis that the esophagus from children may be relatively protected from SARS-
CoV-2 GI infectivity due to lower ACE2 expression and that esophageal Th2 type 
inflammation in children or adults may be particularly protective for infection.  
Discussion 
While the respiratory tract has been considered the main nidus for viral entry, the GI 
tract may also be a primary entry portal for COVID-19.
14
  Both the ileum and esophagus are
considered “high risk” for SARS-CoV-2 infection based on the level of ACE2 transcript. 
15,16
Herein, we provide the first analysis the expression of ACE2, R-A system and TMRPSS2 
genes in EoE and EG versus control esophagi and stomach, using RNAseq data. We have 
found that age and eosinophilic T2 inflammation both influence the expression of the SARS-
COV-2 viral genes required for viral entry.   
These results should be evaluated in organ specific and atopic specific contexts.  
While Radzikowksa et al found no difference in ACE2 expression between bronchial biopsies 
of normal and asthmatic patients, when looked at in the context of the atopic state, Jackson et 
al found lower levels of expression of ACE2 in allergic asthmatic adults and the negative 
correlation of ACE2 expression with IL-13 and IgE levels
4,17
. Similarly, we show here that
pediatric EoE subjects had no overall differences in ACE2/TMPRSS2 expression compared 
to non-inflamed control esophagi but that adult and pediatric EoE patients had significantly 
lower ACE2 and TMPRSS2 expression compared to normal tissue. It is possible that the 
distinct phenotypes of EoE
18
 and asthma may also lead to differential risk of infection.
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The most serious consequence of COVID19 is severe life-threatening pulmonary 
edema and acute respiratory distress syndrome (ARDS).  During ARDS type lung injury, the 
R-A system acts to increase capillary permeability contributing to pulmonary edema. ACE2, 
on the other hand, acts to negatively regulate the effects of the classical R-A system and 
induces an anti-inflammatory effects.
19
  While ACE2 is seemingly protective against severe 
ARDS in the setting of lung injury, it is also the gateway by which SARS-CoV-2 enters the 
mucosal surface.  
We acknowledge that a limitation of this work is that it evaluates only RNA 
expression.  Future work should evaluate ACE2/TMPRSS2 protein-level expression in these 
populations as well as the severity and acquisition rate of SARS-CoV2 in EGID patients 
across ages.  While we have tried to control for differing methodologies across studies, a 
direct comparison of pediatric and adult gastrointestinal tissue would provide superior results. 
In addition, our EGID sample sizes were small and normal tissue RNA sequence data was 
available only in adults.  
In conclusion, we have demonstrated the ACE2/TMPRSS2 has limited gene 
expression in the GI tract and provided potential mechanisms whereby young age and EoE-
associated Th2 inflammation could confer advantages for lower infection rates from 
COVID19 by decreasing the expression of its receptor and protease. These insights may be of 
utility when designing novel SARS-CoV-2 therapies and understanding the clinical course 
and risks of COVID19.   
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Figure 1. Expression of R-A system genes and in EGIDs. (A) EGIDs and associated Th2 
inflammation as well as age effect on TMPRSS2/ACE2 expression. ACE1 (ACE) conversion 
of angiotensin I to angiotensin II causes inflammation and hypertension. ACE2 cleavage of 
angiotensin II to angiotensin 1-7 and binding to Mas receptor (MAS1) decreases blood 
pressure lowering and inflammation. Angiotensinogen (AGT) is cleaved by renin (REN) and 
non-renin EoE-associated proteases, chymase (CMA1) and kallikrein 1 (KLK1) (dashed 
line). (B-D). R-A system and TMPRSS2 transcriptomes in EoE (B) and EG (C) biopsies. 
(TPM:  transcripts per million)  
Figure 2: Age and EoE status effect ACE2/TMPRSS2 gene expression. Expression of 
SARS-CoV2 receptors in (A) normal adult versus pediatric non-inflamed controls, (B) 
normal adult vs. pediatric EoE, and (C) normal adult vs. adult EoE.  
